Efficacy and manageable safety of tagraxofusp in blastic plasmacytoid dendritic cell neoplasm: a case series of pediatric and adolescent/young adult patients

Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) predominantly occurs in adults ≥60 years old; 10–20% of cases are pediatric or adolescent/young adult (AYA) patients. Tagraxofusp (TAG, Elzonris®) is the only approved treatment for BPDCN; in the United States it is approved for patients...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Naveen Pemmaraju, Branko Cuglievan, Joseph Lasky, Albert Kheradpour, Nobuko Hijiya, Anthony S. Stein, Soheil Meshinchi, Craig A. Mullen, Emanuele Angelucci, Luciana Vinti, Tariq I. Mughal, Anna B. Pawlowska
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2024-02-01
Edice:	eJHaem
Témata:	AYA BPDCN CD123 pediatric BPDCN plasmacytoid dendritic cells tagraxofusp
On-line přístup:	https://doi.org/10.1002/jha2.856
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!